Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

The most recent news releases from April 20, 2026, present a dichotomy between regulatory optimism and internal instability. The primary event is the immediate resignation of Chief Executive Officer Michael Cola, with Co-founder Eric So returning as Interim CEO. This follows his appointment just two months prior in February 2026 to lead commercialization efforts. Concurrently, the company issued a statement supporting a new White House Executive Order aimed at advancing psychedelic research and regulatory pathways.

Historically, the company has reported positive clinical momentum. In March 2026, Phase 2 signal detection results for HLP004 (Generalized Anxiety Disorder) showed statistically significant improvements. In February 2026, Q3 financials revealed a cash position of $195.1 million but highlighted an accelerated burn rate with operating expenses rising to $36.7 million per quarter. The company rebranded from Cybin Inc. to Helus Pharma in early 2026.

The CEO transition constitutes a Material - Negative event for the following reasons: - Leadership Instability: Michael Cola was appointed specifically to oversee the "next phase of scale and execution" leading into Phase 3 data readouts (Q4 2026). His departure after only two months suggests potential strategic misalignment or internal friction within the Board. This undermines investor confidence in the company's ability to execute commercialization strategies post-approval. - Timing Risk: The leadership change occurs immediately prior to critical Phase 3 data readouts for HLP003 (Major Depressive Disorder). Uncertainty regarding who will manage the regulatory and commercial launch of a potential blockbuster asset introduces significant execution risk. - Policy Support vs. Fundamentals: While support for the White House Executive Order is positive sentiment, it does not alter the company's fundamental financial or operational trajectory. Regulatory pathways remain subject to FDA discretion regardless of executive orders. This news is routine advocacy and does not offset the leadership risk. - Financial Burn: The Q3 FY2026 results showed a net loss of $42.7 million, a significant increase from $7.5 million in the prior year period. With operating cash outflow at $31.9 million per quarter, the runway is tightening despite the $195.1 million cash balance.

Helus Pharma is a clinical-stage biopharmaceutical company focused on developing novel serotonergic agonists (NSAs) for serious mental health conditions. The company rebranded from Cybin Inc. in February 2026 to reflect its strategic focus. - Flagship Project: HLP003, currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). It holds FDA Breakthrough Therapy designation. - Secondary Program: HLP004, in Phase 2 development for generalized anxiety disorder (GAD), which recently reported positive signal detection data.